BCBS Medical Policy Update – 10.2.2023

Blue Cross and Blue Shield of Kansas (BCBSKS) has published the following updated medical policies:

• Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
• Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
• Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
• Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, HER2, PD-L1, TMB)

Source: https://www.bcbsks.com/providers/medical-policies